Research And Markets Research And Markets
0 CHECKOUT

Essential Thrombocythemia - Pipeline Review, H1 2015

  • ID: 3164974
  • March 2015
  • 85 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • Biogenomics Limited
  • Galena Biopharma, Inc.
  • Gilead Sciences, Inc.
  • Incyte Corporation
  • Italfarmaco S.p.A.
  • Novartis AG
  • MORE

Essential Thrombocythemia - Pipeline Review, H1 2015

Summary

This, ‘Essential Thrombocythemia - Pipeline Review, H1 2015’, provides an overview of the Essential Thrombocythemia’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Essential Thrombocythemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Essential Thrombocythemia and special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities READ MORE >

Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Biogenomics Limited
  • Galena Biopharma, Inc.
  • Gilead Sciences, Inc.
  • Incyte Corporation
  • Italfarmaco S.p.A.
  • Novartis AG
  • MORE

List of Tables
List of Figures
Introduction
REPORT COVERAGE
Essential Thrombocythemia Overview
Therapeutics Development
Pipeline Products for Essential Thrombocythemia - Overview
Pipeline Products for Essential Thrombocythemia - Comparative Analysis
Essential Thrombocythemia - Therapeutics under Development by Companies
Essential Thrombocythemia - Therapeutics under Investigation by Universities/Institutes
Essential Thrombocythemia - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Essential Thrombocythemia - Products under Development by Companies
Essential Thrombocythemia - Products under Investigation by Universities/Institutes
Essential Thrombocythemia - Companies Involved in Therapeutics Development
Aop Orphan Pharmaceuticals AG
Biogenomics Limited
Galena Biopharma, Inc.
Gilead Sciences, Inc.
Incyte Corporation
Italfarmaco S.p.A.
Novartis AG
Onconova Therapeutics, Inc.
PharmaEssentia Corporation
Essential Thrombocythemia - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
anagrelide hydrochloride CR - Drug Profile
Product Description
Mechanism of Action
R&D Progress
anagrelide hydrochloride PR - Drug Profile
Product Description
Mechanism of Action
R&D Progress
erismodegib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
givinostat - Drug Profile
Product Description
Mechanism of Action
R&D Progress
interferon alfa-2b (recombinant) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
momelotinib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
peginterferon alfa-2b - Drug Profile
Product Description
Mechanism of Action
R&D Progress
rigosertib sodium - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ruxolitinib phosphate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules to Inhibit JAK for Oncology and Hematological Disorders - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Essential Thrombocythemia - Recent Pipeline Updates
Essential Thrombocythemia - Dormant Projects
Essential Thrombocythemia - Discontinued Products
Essential Thrombocythemia - Product Development Milestones
Featured News & Press Releases
Nov 18, 2014: Galena Biopharma Completes Enrollment In GALE-401 (Anagrelide Controlled Release) Phase 2 Clinical Trial
Feb 13, 2013: Novartis's Myelofibrosis Drug Jakavi Turned Down By NICE In Draft Guidance
May 31, 2011: YM BioSciences Announces Orphan Drug Designation For JAK1/JAK2 Inhibitor CYT387 In Europe
Dec 06, 2010: Incyte Presents Positive Phase II Trial Results Of INCB18424 In Advanced Polycythemia Vera And Essential Thrombocythemia At ASH Annual Meeting
May 28, 2009: Incyte Provides Update on Special Protocol Assessment for INCB18424 As A New Treatment for Myelofibrosis
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Essential Thrombocythemia, H1 2015
Number of Products under Development for Essential Thrombocythemia - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Development, H1 2015
Products under Development by Companies, H1 2015
Products under Investigation by Universities/Institutes, H1 2015
Essential Thrombocythemia - Pipeline by Aop Orphan Pharmaceuticals AG, H1 2015
Essential Thrombocythemia - Pipeline by Biogenomics Limited, H1 2015
Essential Thrombocythemia - Pipeline by Galena Biopharma, Inc., H1 2015
Essential Thrombocythemia - Pipeline by Gilead Sciences, Inc., H1 2015
Essential Thrombocythemia - Pipeline by Incyte Corporation, H1 2015
Essential Thrombocythemia - Pipeline by Italfarmaco S.p.A., H1 2015
Essential Thrombocythemia - Pipeline by Novartis AG, H1 2015
Essential Thrombocythemia - Pipeline by Onconova Therapeutics, Inc., H1 2015
Essential Thrombocythemia - Pipeline by PharmaEssentia Corporation, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Stage and Target, H1 2015
Number of Products by Stage and Mechanism of Action, H1 2015
Number of Products by Stage and Route of Administration, H1 2015
Number of Products by Stage and Molecule Type, H1 2015
Essential Thrombocythemia Therapeutics - Recent Pipeline Updates, H1 2015
Essential Thrombocythemia - Dormant Projects, H1 2015
Essential Thrombocythemia - Discontinued Products, H1 2015

List of Figures
Number of Products under Development for Essential Thrombocythemia, H1 2015
Number of Products under Development for Essential Thrombocythemia - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Products, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Top 10 Targets, H1 2015
Number of Products by Stage and Top 10 Targets, H1 2015
Number of Products by Top 10 Mechanism of Actions, H1 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
Number of Products by Top 10 Routes of Administration, H1 2015
Number of Products by Stage and Top 10 Routes of Administration, H1 2015
Number of Products by Top 10 Molecule Types, H1 2015
Number of Products by Stage and Top 10 Molecule Types, H1 2015

Note: Product cover images may vary from those shown
3 of 4

Aop Orphan Pharmaceuticals AG
Biogenomics Limited
Galena Biopharma, Inc.
Gilead Sciences, Inc.
Incyte Corporation
Italfarmaco S.p.A.
Novartis AG
Onconova Therapeutics, Inc.
PharmaEssentia Corporation

Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown

RELATED PRODUCTS from Db